<DOC>
	<DOCNO>NCT01011049</DOCNO>
	<brief_summary>The purpose study generate additional data immunogenicity safety revaccination Fluzone Intradermal ( ID ) Fluzone Intramuscular ( IM ) vaccine . Primary Objective : - To evaluate describe safety profile revaccination Fluzone ID participant . Secondary Objective : - To describe immunogenicity follow revaccination Fluzone ID Fluzone IM .</brief_summary>
	<brief_title>Study Influenza Vaccine Revaccination Healthy Adults Previously Vaccinated With Fluzone ID Fluzone IM</brief_title>
	<detailed_description>All participant , previously receive either Fluzone ID Fluzone IM Study FID31 ( NCT 00772109 ) , receive one dose either alternative vaccine .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged 18 64 year day vaccination study FID33 Enrolled complete study FID31 ( NCT 00772109 ) receive correct vaccine ( Fluzone ID Fluzone® IM ) group randomize Informed consent form sign date Able attend schedule visit comply trial procedure For woman childbearing potential , avoid become pregnant ( use effective method contraception abstinence ) least 4 week prior vaccination , least 4 week vaccination Exclusion Criteria : Known systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance For woman childbearing potential : know pregnancy positive serum/urine pregnancy test Breastfeeding woman Participation another clinical trial investigate vaccine , drug , medical device , medical procedure four week precede trial vaccination Planned participation another clinical trial present trial period ( observational trial allow ) Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy Chronic illness , stage could interfere trial conduct completion , opinion investigator Current alcohol abuse drug addiction may interfere subject 's ability comply trial procedure Receipt blood bloodderived product past 3 month , might interfere assessment immune response Receipt vaccination 4 week precede trial vaccination Planned receipt vaccine 4 week follow trial vaccination Known human immunodeficiency virus ( HIV ) , hepatitis B surface ( HBs ) antigen , Hepatitis C seropositivity . Previous vaccination influenza past 6 month trial vaccine another vaccine Thrombocytopenia , bleed disorder anticoagulant 3 week precede inclusion contraindicate IM vaccination Subject deprive freedom administrative court order , emergency setting , hospitalize without his/her consent Neoplastic disease hematologic malignancy , ( localize skin prostate cancer stable time vaccination absence therapy , well subject history neoplastic disease disease free ≥ 5 year exclude ) . Personal family history GuillainBarré Syndrome Temporary A prospective subject include study follow condition and/or symptom resolve : Febrile illness ( temperature ≥ 37.5°C [ ≥ 99.5°F ] ) moderate severe acute illness/infection day vaccination , accord investigator judgment Signs symptom acute infectious respiratory illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Fluzone Vaccine</keyword>
	<keyword>Intradermal Injections</keyword>
	<keyword>Adults</keyword>
</DOC>